Tomoyuki Araya
Kanazawa University
Internal medicineRadiologySurgeryPathologyOncologyRetrospective cohort studyAdverse effectLung cancerChemotherapyNeutropeniaCarcinomaEpidermal growth factor receptorNivolumabGemcitabineVinorelbineGefitinibAdenocarcinomaCarboplatinNon small cellIn patientPhases of clinical researchCancer researchMedicine
45Publications
7H-index
293Citations
Publications 44
Newest
#1Toshiyuki KitaH-Index: 15
#2Tomoyuki ArayaH-Index: 7
Last. Kazuo Kasahara (Kanazawa University)H-Index: 26
view all 6 authors...
Abstract A 79-year-old woman was diagnosed with stage IV (cT1aN1M1, OSS) lung adenocarcinoma with bone metastasis of the right femur. She received nivolumab as a third-line treatment. She developed pain in the right shoulder, left wrist, right knee, and waist as well as a low-grade fever and morning stiffness, after five courses of nivolumab. After closer examination, she was diagnosed with polymyalgia rheumatica (PMR) precipitated by an immune-related adverse event. Nivolumab was discontinued, ...
Source
An 84-year-old man was referred to our out-patient clinic with an elongated mass localized to the retrosternal area that was incidentally identified by computed tomography. On 18F-fluorodeoxyglucose-positron emission tomography, this lesion showed intense tracer uptake. Thus, a surgical biopsy under thoracoscopy was performed. Histological examination revealed dense fibrous tissue associated with inflammatory cell infiltration. The immunoglobulin (Ig) G4/IgG plasma cell ratio was over 90%. Serum...
#1Hideharu KimuraH-Index: 21
#2Takashi SoneH-Index: 12
Last. Kazuo KasaharaH-Index: 26
view all 9 authors...
Awareness of the immune-related adverse event of programmed cell death protein-1 (PD-1) inhibitor-induced pneumonitis is important. Herein, we report the clinical course of 3 patients suspected to have PD-1 inhibitor-induced pneumonitis after cessation of PD-1 inhibitor treatment. In case 1, a 62-year-old man was diagnosed with stage IVA adenocarcinoma. Nivolumab monotherapy was prescribed as second-line therapy and later discontinued due to financial reasons. Seven months after the final admini...
Source
#1Tomoyuki ArayaH-Index: 7
#2Toshiyuki KitaH-Index: 15
Last. Kazuo KasaharaH-Index: 26
view all 6 authors...
A standard chemotherapy regimen for advanced thymic carcinoma has not yet been established. We treated 2 cases of thymic carcinoma with carboplatin plus nanoparticle albumin-bound (nab)-paclitaxel, and nab-paclitaxel maintenance therapy. The first case was a 68-year-old female, admitted for dyspnea and left shoulder pain. Chest computed tomography (CT) showed a huge mass in the anterior mediastinum, pleural and pericardial effusions, and multiple lung metastases. Specimens obtained from the ante...
Source
#1Akira Nakao (Fukuoka University)H-Index: 3
#2Osamu HiranumaH-Index: 4
Last. Koichi Takayama (Kyoto Prefectural University of Medicine)H-Index: 49
view all 29 authors...
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are used for treating EGFR-mutated lung cancer, and osimertinib is effective in cases that acquired T790M mutations after treatment with the first- and second-generation EGFR-TKIs. However, no study has evaluated its safety and efficacy in older patients. This phase II trial (jRCTs071180002) evaluated osimertinib in T790M mutation-positive Japanese patients who were ≥75 years old and had experienced relapse or progression af...
2 CitationsSource
#1Yuichi Tambo (Kanazawa University)H-Index: 5
#2Takashi Sone (Kanazawa University)H-Index: 4
Last. Kazuo Kasahara (Kanazawa University)H-Index: 26
view all 11 authors...
Abstract Background In clinical trials, first-line treatment of pembrolizumab improved overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC) with a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) of 50% or greater. However, data on the efficacy of this treatment between clinical trials and actual clinical practice are inconsistent. Patients and Methods Ninety-five patients with histologically diagnosed advanced or recurrent NSCLC and a PD-L1 TPS score ...
7 CitationsSource
#1Hideharu Kimura (Kanazawa University)H-Index: 21
#2Tomoyuki ArayaH-Index: 7
Last. Kazuo Kasahara (Kanazawa University)H-Index: 26
view all 11 authors...
2 CitationsSource
#1Kazuo KasaharaH-Index: 26
#2Takashi SoneH-Index: 12
Last. Yuichi TamboH-Index: 5
view all 11 authors...
Source
#1Hideyuki KatsuraH-Index: 1
#1Hideyuki KatsuraH-Index: 2
Last. Hiroki MaseH-Index: 1
view all 9 authors...
Background: Nivolumab efficacy in patients with non-small-cell lung cancer (NSCLC) and performance status (PS) of 2-4 is unclear. We aimed to compare survival, treatment efficacy, and safety in patients with NSCLC with poor PS who received nivolumab plus best supportive care (BSC) with those in patients who received BSC alone in a palliative care unit (PCU). Patients and methods: This retrospective study included 99 consecutive patients with NSCLC who received nivolumab plus BSC or BSC alone bet...
9 CitationsSource
#1Satomi Kasashima (Kanazawa University)H-Index: 22
#2Atsuhiro KawashimaH-Index: 28
Last. Mitsutaka SuzukiH-Index: 1
view all 7 authors...
OBJECTIVE: Immunoglobulin (Ig)G4-related disease is a recently described systemic immune-mediated fibro-inflammatory disease that frequently occurs in tumorous form. Herein, we elucidated the clinicopathological and cytological characteristics of IgG4-related pleural lesions (PLs). PATIENTS AND METHODS: Among 22 patients with fibro-inflammatory PLs of idiopathic aetiology, eight cases were diagnosed as IgG4-PL and the remaining 14 as non-IgG4-PL according to comprehensive diagnostic criteria for...
3 CitationsSource